New drug tested for serious blistering skin disease
NCT ID NCT02226146
Summary
This small, early-stage study tested an experimental drug called bertilimumab in 11 older adults newly diagnosed with moderate to severe bullous pemphigoid, a painful autoimmune disease that causes large skin blisters. The main goal was to check the drug's safety and see if it could help reduce disease activity and the need for steroid medications. Researchers measured changes in blister counts, itching, and quality of life over the course of treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PEMPHIGOID, BULLOUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Iowa City, Iowa, United States
-
Research Site
Buffalo, New York, United States
-
Research Site
New York, New York, United States
-
Research Site
Durham, North Carolina, United States
-
Research Site
Cleveland, Ohio, 10900, United States
-
Research Site
Salt Lake City, Utah, United States
-
Research Site
Ramat Gan, 5262100, Israel
-
Research Site
Tel Aviv, 64239, Israel
Conditions
Explore the condition pages connected to this study.